Overview

Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
Details
Lead Sponsor:
Pfizer
Treatments:
Exemestane